These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9372064)

  • 21. Pathogenesis and treatment of sickle cell disease.
    Bunn HF
    N Engl J Med; 1997 Sep; 337(11):762-9. PubMed ID: 9287233
    [No Abstract]   [Full Text] [Related]  

  • 22. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
    Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimizing hydroxyurea therapy for sickle cell anemia.
    Ware RE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():436-43. PubMed ID: 26637755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients.
    Teixeira SM; Cortellazzi LC; Grotto HZ
    Braz J Med Biol Res; 2003 Oct; 36(10):1289-92. PubMed ID: 14502358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease.
    Selby R; Nisbet-Brown E; Basran RK; Chang L; Olivieri NF
    Blood; 1997 Jul; 90(2):891-3. PubMed ID: 9226193
    [No Abstract]   [Full Text] [Related]  

  • 26. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
    Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapies to increase fetal hemoglobin in sickle cell disease.
    Steinberg MH
    Curr Hematol Rep; 2003 Mar; 2(2):95-101. PubMed ID: 12901139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sickle cell disease: new insights into pathophysiology and treatment.
    Inati A; Koussa S; Taher A; Perrine S
    Pediatr Ann; 2008 May; 37(5):311-21. PubMed ID: 18543542
    [No Abstract]   [Full Text] [Related]  

  • 29. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
    Ware RE; Helms RW;
    Blood; 2012 Apr; 119(17):3925-32. PubMed ID: 22318199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxyurea therapy in thalassemia.
    Loukopoulos D; Voskaridou E; Stamoulakatou A; Papassotiriou Y; Kalotychou V; Loutradi A; Cozma G; Tsiarta H; Pavlides N
    Ann N Y Acad Sci; 1998 Jun; 850():120-8. PubMed ID: 9668534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging disease-modifying therapies for sickle cell disease.
    Carden MA; Little J
    Haematologica; 2019 Sep; 104(9):1710-1719. PubMed ID: 31413089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
    Dover GJ
    Ann N Y Acad Sci; 1998 Jun; 850():80-6. PubMed ID: 9668530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atrial septal defect closure on cardiopulmonary bypass in a sickle cell anemia: role of hydroxyurea and partial exchange transfusion.
    Gosavi KS; Dash SK; Shah BN; Upasani CB
    Ann Card Anaesth; 2010; 13(2):145-7. PubMed ID: 20442545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease.
    Cui S; Engel JD
    Adv Exp Med Biol; 2017; 1013():177-202. PubMed ID: 29127681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sickle cell anaemia: current therapies.
    Vermylen C
    Transfus Apher Sci; 2013 Oct; 49(2):151-4. PubMed ID: 23954416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.
    Brugnara C; Gee B; Armsby CC; Kurth S; Sakamoto M; Rifai N; Alper SL; Platt OS
    J Clin Invest; 1996 Mar; 97(5):1227-34. PubMed ID: 8636434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Kassim AA; DeBaun MR
    Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.